By Fineline Cube 
China-based Annoroad Gene Technology (Beijing) Co., Ltd. has submitted an initial public offering (IPO) filing to the Hong Kong Stock Exchange, with details regarding the unit price and other key terms remaining undisclosed at this stage.
Company Overview
Since its establishment in 2012, Annoroad Gene Technology has been dedicated to the development of in vitro diagnostics (IVD) medical devices and multi-omics life science research services, primarily based on molecular diagnostics. The company’s clinical sequencing solutions encompass self-produced IVD detection kits, gene sequencers, bioinformatics analysis software, and associated technical support and laboratory design services.
Market Position
Annoroad’s customer base primarily consists of hospitals and independent clinical laboratories (ICLs) certified for prenatal diagnosis. The company holds a significant market share in China’s noninvasive prenatal testing (NIPT) sector, thanks to its NIPT kit, a Category 3 product approved in 2017. This kit is designed to detect the three most common chromosomal abnormalities: Trisomy 21, 18, and 13.-Fineline Info & Tech